View CervoMed Inc. CRVO stock quote prices, financial information, real-time forecasts, and company news from CNN.

CervoMed announced a $10.5 million private placement financing, with participation from institutional healthcare investors and company insiders.

The new patent for neflamapimod covers the treatment of dementia with Lewy bodies in patients without significant signs of Alzheimer’s disease.

Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain ...

CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB). The results are based on the final analyses of ...

Fintel reports that on March 13, 2025, Chardan Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Neutral to Buy. As of March 4, 2025, the average one-year price target for CervoMed is ...

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies ...

On June 22, 2026, CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of $10 million before fees and expenses. H.C.

Fintel reports that on February 19, 2025, D. Boral Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to Buy. As of February 18, 2025, the average one-year price target for CervoMed ...

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with ...